• H2020
• Excellent Science

Finnish company Brainshake has raised €3.5m in funding. The investment will be used to advance regulatory approval and internationalisation of its blood analysis service.

Brainshake’s blood analysis service provides more than 220 biomarkers from a single blood sample – 50 times more than commonly used laboratory methods.

Biomarkers reflect the health state of an individual and can be used to predict risk in chronic diseases. Brainshake’s blood analysis has been backed by 100 peer reviewed scientific publications, and is used by leading universities globally.

Teemu Suna, chief executive officer (CEO) of Brainshake, said: “Our technology has been proven by peer reviewed science and the epidemiological studies show the power of our data in risk assessment of chronic diseases.

“Now we are bringing the technology to routine healthcare with the ultimate target to enable prevention of the world’s number one health problem.”

The investment is led by Finnish growth venture Cor Group, who join Brainshake as a shareholder and long-term strategic partner.

Olli Karhi, board member of Cor Group, said: “We have worked in the global healthcare market for nearly 30 years, and consider Brainshake’s blood analysis highly impressive.

“We look forward to working together to create a global market leader and to advance the company’s mission to transform preventive medicine in chronic diseases together with our group.

“Our goal is to work with Brainshake as a long-term strategic partner, an active member of the board and co-owner.”